Data from the MIV-711 phase II program to be presented at the OARSI world congress
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis Research Society International (OARSI) world congress, which will take place 2-5 May in Toronto, Canada. Data from the six months’ open label extension study of MIV-711 in patients with osteoarthritis will be presented. The poster will be presented by the study’s lead investigator Dr. Philip Conaghan, Professor of Musculoskeletal Medicine at the University of Leeds in the UK, on May 3 and 4: Abstract 726: Safety and